aTyr Pharma Details New Phase 3 Study for Efzofitimod in Pulmonary Sarcoidosis, Plans June IND Filing
ATYR sits 42% above its 52-week low of $0.395 on elevated volume (2.0× avg).
Summary
aTyr Pharma outlined the detailed design for its new Phase 3 study (C-006) for efzofitimod in pulmonary sarcoidosis, targeting patients with restrictive disease and planning a June 2026 IND filing.
Key Events · Product Development and Regulatory · ATYR
-
New Phase 3 Study Design Detailed
The company provided the detailed design for its new Phase 3 study (C-006) for efzofitimod in pulmonary sarcoidosis, targeting approximately 372 patients with restrictive disease.
-
Primary Endpoint Defined
The C-006 study's primary endpoint will be the change from baseline in Forced Vital Capacity (FVC) at Week 48.
-
IND Filing Planned for June 2026
aTyr Pharma intends to file an Investigational New Drug (IND) application for the C-006 study in June 2026, moving towards trial initiation.
-
FDA Alignment on Study Path
The new study design incorporates feedback from a Type C meeting with the FDA, which supported FVC and KSQ-L as clinically meaningful endpoints.
Analysis · ATYR · Life Sciences
This filing provides the detailed design for aTyr Pharma's new Phase 3 study (C-006) for efzofitimod in pulmonary sarcoidosis, following previous announcements of FDA feedback and a revised path forward. The specifics of the study, including the target population, primary endpoint (FVC), and dosing regimen, are crucial for the company's lead asset, especially after the prior Phase 3 failure and partnership termination. The plan to file an Investigational New Drug (IND) application in June 2026 indicates a near-term progression towards initiating this pivotal trial.
At the time of this filing, ATYR was trading at $0.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.6M. The 52-week trading range was $0.40 to $7.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.